Chantal Kuhn

Chantal Kuhn is an accomplished professional in the field of immunology and cell therapy, currently serving as Director of Bioscience Immunology Early Respiratory & Immunology at AstraZeneca since April 2024. Prior experience includes leadership roles at Clade Therapeutics as Director and Head of T Cell Programs, focusing on the development of iPSC derived cell therapies, and at Takeda Oncology, where contributions involved advancing next-generation cell therapies for cancer. Chantal's academic background includes a Postgraduate Degree in Immunology from Harvard Medical School, a PhD in Immunology from Université Paris Cité, and a degree in Molecular Medicine from FAU Erlangen-Nürnberg, complemented by research training at distinguished institutions such as Brigham and Women's Hospital and INSERM.